White House Watch: Still Anyone’s
White House Watch: Still Anyone’s Race
Thursday, October 27, 2016
Both major party candidates are creeping up in the closing weeks of the presidential campaign, according to the latest Rasmussen Reports White House Watch.
The new national telephone and online survey of Likely U.S. Voters still finds Democrat Hillary Clinton with a one-point lead over Republican Donald Trump – 45% to 44%. Libertarian Gary Johnson remains at a low of four percent (4%), and Green Party nominee Jill Stein earns just one percent (1%) of the vote. Two percent (2%) like some other candidate, and four percent (4%) are undecided. (To see survey question wording, click here.)
Yesterday, it was Clinton 44%, Trump 43%. Clinton started the week down by two points to Trump but edged ahead on Tuesday. Given the survey’s +/- 2.5% margin of error, however, the race remains anyone’s call.
Eighty-seven percent (87%) say they are certain already of how they will vote. Among these voters, it’s tied – Clinton 48%, Trump 48%, with Johnson at four percent (4%). Among those who still could change their minds between now and Election Day, it’s Clinton 43%, Trump 34%, Johnson 14% and Stein 10%.
Generally speaking, support for third-party candidates fades as Election Day nears and their voters opt for one of the two major party nominees. However, many expected third-party candidates to do better this year because of the unpopularity of Clinton and Trump. But Johnson peaked at nine percent (9%) support in September. Stein has never earned more than three percent (3%) of the vote.
Rasmussen Reports updates its White House Watch survey daily Monday through Friday at 8:30 am Eastern based on a three-day rolling average of 1,500 Likely U.S. Voters.
(Want a free daily e-mail update? If it's in the news, it's in our polls). Rasmussen Reports updates are also available on Twitter or Facebook.
The survey of 1,500 Likely Voters was conducted on October 24-26, 2016 by Rasmussen Reports. The margin of sampling error is +/- 2.5 percentage points with a 95% level of confidence. Field work for all Rasmussen Reports surveys is conducted by Pulse Opinion Research, LLC. See methodology.
[Rasmussen Reports analysts Amy Holmes and Fran Coombs are available for interested media. Please call 732-776-9777 ext. 205 for interviews.]
Trump is still slightly ahead in reliably Republican Utah despite a spirited challenge from Republican-turned-Independent Evan McMullin. Congressman Jason Chaffetz who withdrew his support from Trump after the release of a video showing the nominee making crude sexual comments now says he will vote for Trump anyway.
Nationally, both Clinton and Trump earn 81% support from the voters in their respective parties and 12% of the vote from those in each other’s party. Voters not affiliated with either major party prefer Trump 42% to 35% and give Johnson 10%. He and Stein get low single-digit support elsewhere.
The dueling gender gaps remain unchanged. Clinton leads by 10 points among women; Trump is ahead by nine among men.
The Democrats has a sizable lead among those under 40, while their elders continue to favor her GOP rival.
Trump is still well ahead among whites but trails by dramatic margins among black and other minority voters.
Unaffiliateds, younger voters and other minorities, however, are less certain of their vote than the others.
Voters think Clinton has more to hide than Trump does.
Trump is calling for term limits on members of Congress even though his party currently controls both the House of Representatives and the Senate. Voters agree more strongly than ever with the need for term limits.
Clinton now leads Trump in the key state of Nevada.
Skyrocketing premiums for those who purchased their health insurance through Obamacare exchanges has Clinton on the defensive. She’s promised increased federal subsidies, but voters oppose taxpayer help to offset these rate increases.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Taking New Strides in Epilepsy Treatment Today, we’ve got SK Biopharmaceuticals banging on the FDA’s door with a pile of paperwork. They’re pushing for the green light on cenobamate to tackle primary generalized tonic-clonic (PGTC) seizures, plus expand its use to pediatric patients with the focal-onset seizure condition. Now, if you think it sounds like a big...
Continue Reading
Pioneering New Fronts in Education with AI Elite Academic Academy, a stalwart in California's public charter school landscape, has just taken a significant stride forward by stepping into the EDSAFE AI Alliance District Policy Lab. The move, announced in early November 2026, sees Elite diving into the intricate world of artificial intelligence in education, with a pointed...
Continue Reading
Forging a New Path for an Age-Old Craft A splash of tradition with a shot of modern flair—that's where Xifeng Liquor is heading as it mixes baijiu's rich history with the conveniences of 21st-century services. Zhang Zheng, the head honcho at Shaanxi Xifeng Liquor Co., Ltd., laid out this ambitious playbook at a big-deal consumer brands shindig in Baoji City. This isn't...
Continue Reading
Yealink Sets the Stage for AI Conversations in Munich Ah, the buzz of innovation fills the air once again, as Yealink brings a dizzying array of tech bigwigs together at the Workplace Forward Summit in Munich. This ain't your regular business shindig—this is where the gears of the AI-powered future get some heavy oiling. Imagine 400 industry stalwarts, tech gurus,...
Continue Reading
A Bird's Eye View on Lemon Grove's Bold Stand The folks in Lemon Grove, California, just sent out a loud and clear message: put an end to the inhumane sale of birds in pet stores. With 65% of voters backing Measure E, they've decided that birds fly best when they aren't part of a retail circus. Under this new rule, stores can only put birds up for adoption if they're...
Continue Reading
Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...
Continue Reading
Cybersecurity Takes Center Stage at NJII In the world of defense and technology, cybersecurity isn't just about locking the front door—it's about fortifying the entire fortress. And it looks like the New Jersey Innovation Institute (NJII) just added a hefty layer of armor to theirs. Grabbing the Cybersecurity Maturity Model Certification (CMMC) Level 2 is no small feat,...
Continue Reading
Sealing the Deal with Strategic Long-term Goals Alright, here’s the scoop straight outta Dortmund. Borussia Dortmund and SPORTFIVE have penned themselves a cushy deal lasting till 2034. That’s right—eight more solid years. Talk about shuffling the deck with some planning foresight, huh? Been hitting shoulders since '99, these two, so this ain’t just another...
Continue Reading
Shareholder Rights On The Line You ever get that itch, the one that whispers something's off with a company? Well, that itch might be turning into a rash at Domino's Pizza, Inc. (NASDAQ: DPZ). Shareholders are being nudged to jump into the fray as Halper Sadeh LLC investigates potential wrongdoings by some of the pizza titan's bigwigs. The spotlight is on whether these...
Continue Reading
Greasezilla Steps Up for FOG Processing If there’s one thing that makes dealing with wastewater a greasy business, it’s FOG - fats, oils, and grease. It’s the stuff nightmares are made of for any utility trying to keep their pipes clear and their operations running smooth. Now, Greasezilla is stepping into the spotlight at one of the country's largest wastewater...
Continue Reading
Top 5 Most Recently Viewed Articles
Enlivex Advances into Clinical Trials for TMJ Osteoarthritis Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a promising clinical-stage immunotherapy company specializing in macrophage reprogramming, has recently received regulatory clearance to initiate a Phase I clinical trial. This trial aims to assess the safety, tolerability, and initial efficacy of the company’s...
Continue Reading
BYDFi Triumphs at the TrustFinance Performance Awards SINGAPORE – In an impressive recognition of its achievements, BYDFi has secured the prestigious Trusted Exchange Award at the TrustFinance Performance Awards 2025. This accolade highlights the platform's unwavering dedication to transparency, security, and excellence in the rapidly evolving crypto trading landscape....
Continue Reading
Matt Lambert Named 2025 Facility Manager of the Year This recognition underscores Lambert's significant role in enhancing Mirasol's racquet sports offerings. The Country Club at Mirasol proudly announces that General Manager/COO Matt Lambert has been awarded the prestigious title of 2025 Facility Manager of the Year by the Racquet Sports Professional Association (RSPA),...
Continue Reading
Gladstone Capital Corporation Achieves New Stock Milestone Gladstone Capital Corporation (NASDAQ: GLAD) has recently marked a significant milestone by reaching a 52-week high of $24.74. This impressive achievement indicates a thriving phase for the investment company, especially as it showcases a remarkable 1-year growth change of 26.8%. Such progress reflects a growing...
Continue Reading
Inlyte Energy Strengthens Its Leadership with an Expert Advisory Board Inlyte Energy has taken a significant step forward in its mission to lead the energy storage industry by forming a new advisory board. This board consists of highly respected industry experts: former Federal Energy Regulatory Commission (FERC) Chairman Jon Wellinghoff, Dr. Peter Lilienthal, and Richard...
Continue Reading